Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 147 MM
2024-511334-12-00Phase 2Authorised
- Sponsor
- HOVON
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial in smoldering multiple myeloma (SMM) and multiple myeloma (MM) comparing Carfilzomib + lenalidomide + dexamethasone with Lenalidomide + dexamethasone (2 arms). Primary endpoint: MRD negativity rate by NGF after cycle 9. Planned start Sep 2024; status: authorised.
02
Drugs
carfilzomiblenalidomidedexamethasone
03
Conditions
smoldering multiple myeloma (SMM)multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-511334-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511334-12-00.